Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics


Trillium Therapeutics Inc. (TRIL): $18.44

0.47 (+2.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRIL Stock Price Chart Interactive Chart >

Price chart for TRIL

TRIL Price/Volume Stats

Current price $18.44 52-week high $20.96
Prev. close $17.97 52-week low $5.80
Day low $17.83 Volume 26,174,700
Day high $18.49 Avg. volume 1,866,404
50-day MA $17.69 Dividend yield N/A
200-day MA $11.97 Market Cap 1.94B

Trillium Therapeutics Inc. (TRIL) Company Bio


Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.


TRIL Latest News Stream


Event/Time News Detail
Loading, please wait...

TRIL Latest Social Stream


Loading social stream, please wait...

View Full TRIL Social Stream

Latest TRIL News From Around the Web

Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.

Trillium Therapeutics gets Canada, HSR approval for sale to Pfizer

Trillium Therapeutics (NASDAQ:TRIL) disclosed that applicable waiting periods under the Competition Act in Canada and HSR in the U.S. expired on Monday in regards to its $2.3B sale to Pfizer  (NYSE:PFE). The closing of the transaction is expected to occur on or about tomorrow, according to an 8-K filing. Earlier,...

Seeking Alpha | November 17, 2021

7 of the Best Stocks to Buy for Their Free Cash Flow

These stocks to buy have a stable business outlook and robust free cash flows.

Faisal Humayun on InvestorPlace | November 11, 2021

Geode Capital Management LLC Acquires 766,327 Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL)

Geode Capital Management LLC lifted its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 1,041.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 839,889 shares of the biotechnology companys stock after acquiring an additional 766,327 shares during []

Dakota Financial News | November 10, 2021

Trillium Therapeutics Inc. (NASDAQ:TRIL) Given Consensus Recommendation of Hold by Analysts

Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) have been given a consensus rating of Hold by the eight research firms that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers []

Dakota Financial News | November 7, 2021

Trillium Therapeutics Inc. (NASDAQ:TRIL) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp increased its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 56.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,650 shares of the biotechnology company’s stock after purchasing an additional 29,450 shares during the quarter. Stifel Financial Corp […]

Transcript Daily | November 5, 2021

Read More 'TRIL' Stories Here

TRIL Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 180.24%
3-year 5,487.88%
5-year 309.78%
YTD N/A
2021 0.00%
2020 1,328.16%
2019 -39.77%
2018 -76.41%
2017 28.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5057 seconds.